The ADCY5 gene (Adenylate Cyclase 5) encodes adenylate cyclase 5 (AC5), a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP). AC5 is one of ten mammalian adenylate cyclase isoforms and is particularly abundant in the striatum and other brain regions involved in motor control and reward processing.[1] This enzyme serves as a critical downstream effector of G protein-coupled receptors (GPCRs), particularly those coupled to Gαs proteins, including dopamine D1 receptors, adenosine A2A receptors, and β-adrenergic receptors.[2]
ADCY5 plays essential roles in basal ganglia function, integrating signals from multiple neurotransmitters to regulate motor activity, motor learning, and habit formation. Dysregulation of AC5-mediated cAMP signaling has been implicated in several neurodegenerative diseases, most notably Parkinson's disease and Huntington's disease, as well as in familial movement disorders caused by ADCY5 mutations.[3]
| ADCY5 Gene Summary | |
|---|---|
| Gene Symbol | ADCY5 |
| Full Name | Adenylate cyclase 5 |
| Chromosomal Location | 3q21.1 |
| NCBI Gene ID | [112](https://www.ncbi.nlm.nih.gov/gene/112) |
| OMIM | [600293](https://www.omim.org/entry/600293) |
| Ensembl ID | ENSG00000108055 |
| UniProt ID | [O76074](https://www.uniprot.org/uniprot/O76074) |
| Protein Length | 1264 amino acids |
| Expression | Highest in striatum, nucleus accumbens, cortex |
| Associated Diseases | PD, HD, familial dyskinesia, chorea |
The ADCY5 gene spans approximately 67 kb on chromosome 3q21.1 and consists of 34 exons. The gene follows a typical pattern of mammalian adenylate cyclases, with a modular structure encoding distinct functional domains.[4]
ADCY5 belongs to the Class III adenylate cyclase family, which is conserved from bacteria to humans. The ten mammalian ADCY isoforms (ADCY1-10) arose through gene duplication events during vertebrate evolution. ADCY5 and ADCY6 form a closely related pair, sharing approximately 75% amino acid identity and similar expression patterns, particularly in neuronal tissues.[5]
Adenylate cyclase 5 is a large integral membrane protein (approximately 150 kDa) with a characteristic architecture consisting of:
The catalytic activity resides in the C1 and C2 domains, which form a dimer that constitutes the functional enzyme core. Each catalytic domain contributes distinct residues to the active site, with the C2 domain primarily responsible for ATP binding and the C1 domain providing catalytic residues that facilitate the cyclization reaction.[1:1]
AC5 activity is tightly regulated through multiple mechanisms:
AC5 catalyzes the reaction:
ATP → cAMP + PPi (pyrophosphate)
This reaction produces the second messenger cAMP, which activates protein kinase A (PKA), Epac (Exchange protein activated by cAMP), and cyclic nucleotide-gated (CNG) ion channels.[2:1]
ADCY5 exhibits a highly region-specific expression pattern within the central nervous system:
| Brain Region | Expression Level | Functional Significance |
|---|---|---|
| Striatum (caudate, putamen) | Very High | Motor control, habit learning |
| Nucleus accumbens | High | Reward processing, motivation |
| Olfactory tubercle | High | Olfactory signaling |
| Cerebral cortex | Moderate | Cortical processing |
| Hippocampus | Moderate | Memory, plasticity |
| Substantia nigra (pars compacta) | Moderate | Dopaminergic signaling |
| Cerebellum | Low-Moderate | Motor coordination |
The striatal expression of ADCY5 is particularly prominent in medium spiny neurons (MSNs), which constitute approximately 95% of striatal neurons and are the primary projection neurons of the basal ganglia.[3:1]
Within neurons, AC5 is primarily localized to the plasma membrane of dendritic shafts and dendritic spines, positioning it to respond to neurotransmitter receptors at synaptic sites. This subcellular distribution enables efficient coupling between receptor activation and second messenger production.[4:1]
ADCY5 is also expressed in several peripheral tissues, including:
ADCY5 is a primary effector of dopamine D1 receptor (D1R) signaling in the striatum. D1 receptors are coupled to Gαs/olf, and their activation directly stimulates AC5 activity, leading to increased cAMP production and PKA activation.[5:1]
This signaling cascade is critical for:
The D1R-AC5-PKA pathway is particularly important in the direct pathway of the basal ganglia, which facilitates movement. Dysfunction at any point in this cascade can lead to movement disorders.[3:2]
Adenosine A2A receptors, which are highly enriched in striatal projection neurons (particularly in indirect pathway MSNs), also couple to Gαs and stimulate AC5. This creates an important interaction between dopaminergic and adenosine signaling in the basal ganglia.[2:2]
A2A receptor antagonists (such as caffeine) produce their motor-activating effects partly through disinhibition of AC5 activity in striatal neurons.
ADCY5 responds to multiple neurotransmitters and neuromodulators:
Clinical Features:
Genetics:
Mechanism:
ADCY5 plays several roles in Parkinson's disease pathophysiology:
D1 receptor signaling: Loss of dopaminergic neurons in substantia nigra reduces D1R-AC5 signaling in the direct pathway, contributing to bradykinesia
Dyskinesia development: Levodopa-induced dyskinesias (LIDs) involve aberrant cAMP signaling, including AC5 dysregulation
Genetic modifiers: ADCY5 polymorphisms have been associated with:
Neuroprotection: AC5 activity may be neuroprotective; reduced cAMP signaling could contribute to neurodegeneration
In Huntington's disease, AC5 function is altered in striatal neurons:
The degeneration of striatal medium spiny neurons in HD involves dysfunction of multiple signaling pathways, including cAMP production via AC5.[3:3]
| Approach | Status | Description | Clinical Context |
|---|---|---|---|
| AC5 inhibitors | Preclinical | Small molecules targeting AC5 catalytic activity | Levodopa-induced dyskinesia |
| AC5 activators | Preclinical | Positive modulators of AC5 | Neuroprotection in PD |
| Gene therapy | Preclinical | AAV-mediated AC5 modulators | PD, HD |
| Allosteric modulators | Preclinical | Target specific conformational states | Selective targeting |
| AKAP disruptors | Preclinical | Disrupt AC5-AKAP interactions | Subunit-selective effects |
AC5-selective inhibitors: Developing inhibitors that selectively target AC5 over other isoforms to avoid off-target effects
Positive allosteric modulators: Compounds that enhance AC5 activity in a use-dependent manner
Gene therapy approaches: Viral vector delivery of AC5 modulators to striatal neurons
Combination therapies: Targeting AC5 alongside other PD-relevant pathways (e.g., dopamine replacement, MAO-B inhibition)
Isoform selectivity: How can we achieve truly selective targeting of AC5 over other neuronal adenylate cyclases?
Cell-type specificity: What determines AC5 function in different neuronal populations?
Temporal dynamics: How does AC5 activity change during disease progression?
Compensatory mechanisms: What happens when AC5 is chronically inhibited?
Network effects: How does AC5 modulation affect basal ganglia circuit function?